This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Should You Buy Thermo Fisher (TMO) Ahead of Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
KLA-Tencor (KLAC) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
KLA-Tencor's (KLAC) fiscal second-quarter results are likely to reflect strong demand in Process Control systems and solid execution.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $518.83, marking a +0.82% move from the previous day.
Thermo Fisher (TMO) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher's (TMO) Life-Science Solutions and Specialty Diagnostics segments are expected to have contributed, banking on COVID-19-led growing healthcare needs.
Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout
by Zacks Equity Research
The addition of Henogen's manufacturing capabilities in Europe complement Thermo Fisher's (TMO) four development and manufacturing sites in North America.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $503.14 in the latest trading session, marking a +1.25% move from the prior day.
The Zacks Analyst Blog Highlights: Amazon, Thermo Fisher, Eli Lilly, Google and CVS Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Thermo Fisher, Eli Lilly, Google and CVS Health
Thermo Fisher (TMO) Rides on End Market Growth Amid Pandemic
by Zacks Equity Research
Thermo Fisher (TMO) launches Amplitude Solution to automate high-throughput PCR-based testing and significantly expands capacity for viral transport media production in Europe.
Top Analyst Reports for Amazon, Thermo Fisher & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Thermo Fisher Scientific (TMO), and Eli Lilly (LLY).
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $485.21 in the latest trading session, marking a +1.57% move from the prior day.
Why the Earnings Surprise Streak Could Continue for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $465.78 in the latest trading session, marking a +0.88% move from the prior day.
Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $458.34, moving -1.47% from the previous trading session.
Medtronic (MDT) Gets Canada Nod for Micra AV to Treat AV Block
by Zacks Equity Research
With the approval, Medtronic (MDT) aims to strengthen its Cardiac and Vascular Group business globally.
Why You Should Retain Avanos Medical (AVNS) Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), courtesy of solid prospects.
Bruker (BRKR) Launches PCR Panel, Expands Testing Portfolio
by Zacks Equity Research
Bruker's (BRKR) winter four-plex panel is expected to facilitate diagnosis and patient management by facilitating the use of saliva samples as well.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
IDEXX (IDXX) Gains on CAG Sales, Global Growth Remains Robust
by Zacks Equity Research
IDEXX (IDXX) sees sturdy gains in CAG Diagnostics recurring revenues, supported by high organic gains in both U.S. and International markets.
Syneos Health (SYNH) Buys Illingworth Research, Expands CRO Base
by Zacks Equity Research
Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.
Globus Medical (GMED) Gains From Robot Sales Amid Pandemic Blues
by Zacks Equity Research
Globus Medical (GMED) saw a visible rebound in its revenue trend in the third quarter.
Abbott (ABT) Broadens Pediatric Client Base With New Labeling
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 LVAD or heart pump is an implantable device that pumps blood through the body in people whose hearts are too weak to do so naturally.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $464.51, marking a +1.47% move from the previous day.
Varian (VAR) Inks Deal With Yonsei Cancer Center in Korea
by Zacks Equity Research
Varian (VAR) will be coordinating with Yonsei Cancer Center on formulating AI solutions, which are proven to upgrade early detection of cancer.
5 MedTech Stocks That Have Outperformed the Industry in 2020
by Debanjana Dey
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
Cerner (CERN) to Buy Kantar Health to Enhance Clinical Research
by Zacks Equity Research
Cerner (CERN) agrees to acquire Kantar Health to drive safety and efficiency of clinical research across life sciences, pharmaceuticals and health care.